We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Population Pharmacokinetics of Linezolid

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01200654
First Posted: September 13, 2010
Last Update Posted: October 23, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Toulouse
  Purpose

Linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. It has a specific inhibitory activity against Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers. The intensive care units patients, with mechanical ventilation, and with severe sepsis, represent highly heterogeneous population responsible of hight variability in pharmacokinetics parameters (augmentation in total volume of distribution, modification in glomerular filtration) wich can lead to antibiotic inefficacy.

In a first time, this study describe the pharmacokinetics of Linezolid in intensive care units patients with severe MRSA infection. The aim of this study is to define and validate a population pharmacokinetic model including the influence of patients' characteristic on the pharmacokinetics of Linezolid.


Condition Intervention Phase
Methicillin-Resistant Staphylococcus AureuS Drug: Linezolid Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Population Pharmacokinetics of Linezolid in Intensive Care Units Patients Treated for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections

Resource links provided by NLM:


Further study details as provided by University Hospital, Toulouse:

Primary Outcome Measures:
  • The first objective of this study is to research the influence of patients' characteristic on the pharmacokinetics of Linezolid. [ Time Frame: Blood sampling are collected on the second day after begining of treatment at the following time : H1, H2, H3, H6 and H12. ]
    The following demographic, clinical and biological parameters were collected as possible covariates: age, gender, bodyweight, height, etiology of incoming, mechanical ventilation, serum creatinine, proteins, Blood Urea Nitrogen (BUN), leukocyte counts, haemoglobin, C-reactive protein (CRP), and simplified acute physiology scores (SAPS I and II).


Secondary Outcome Measures:
  • The secondary outcome measure are the verification of the clinical and bactériological efficacies, and to look after the residual concentration [ Time Frame: At the 48th hours of treatment ]

Enrollment: 60
Study Start Date: November 2007
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MRSA Infections
Methicillin-Resistant Staphylococcus aureus Infections
Drug: Linezolid
Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
Other Name: Pharmacokinetics of Linezolid

Detailed Description:

The demographic, clinical and biological parameters are collected. Patients receive Linezolid as 600 mg twice a day during an administration of 60 minutes.

Blood sampling are collected on the second day after beginning of treatment at the following time : H1, H2, H3, H6 and H12.

The population pharmacokinétics analysis will be carried out using Monolix, a software for the analysis of nonlinear mixed effects models.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In-patient stay in intensive care
  • Over 18 years old
  • Presenting with MRSA nosocomial pneumonia or bacteraemia with a strain thought to be sensitive to Linezolid
  • Simplified Acute Physiological Score (SAPS) II > 20
  • Expected duration of life > 7 days.

Exclusion Criteria:

  • History of allergy to linezolid or any of the antibiotics used
  • Isolation of MRSA resistant to linezolid
  • Lack of seeds
  • Pregnancy and lactation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01200654


Sponsors and Collaborators
University Hospital, Toulouse
Investigators
Principal Investigator: Bernard Georges, PhMD UH Toulouse
  More Information

Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT01200654     History of Changes
Other Study ID Numbers: 06 049 02
First Submitted: September 10, 2010
First Posted: September 13, 2010
Last Update Posted: October 23, 2012
Last Verified: October 2012

Keywords provided by University Hospital, Toulouse:
Population pharmacokinetics
Linezolid
Monolix
nonlinear mixed effects models

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Linezolid
Methicillin
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action